Furthermore, the NCCN recommends that PMRT should be “strongly considered” in patients with 1 to 3 positive lymph nodes taking into account other risk factors such as age, comorbidities, life-expectancy, the tumor size, the ratio of positive lymph nodes, tumor grade, LVSI, or biologic tumor features (i.e., hormonal receptor status and targetable mutations). This evidence concerns the gene NR4A1 and neoplasm.